Current Rheumatology Reports

, Volume 11, Issue 4, pp 248–254 | Cite as

Epidemiology of atherosclerosis in systemic lupus erythematosus

  • Mandana Nikpour
  • Murray B. Urowitz
  • Dafna D. Gladman


Patients with systemic lupus erythematosus (SLE) have a significantly increased risk of atherosclerotic coronary events. Traditional risk factors, such as hypertension and hypercholesterolemia, only partly account for the increased risk of coronary disease in SLE. Other important risk factors include disease and treatmentrelated factors. Novel markers of coronary risk in SLE are being investigated. Several methods have been used to detect subclinical atherosclerosis in patients with SLE. Among these, scintigraphic myocardial perfusion defects have been shown to be predictive of subsequent coronary events, independent of traditional Framingham risk factors. Although the aggressive treatment of reversible risk factors, such as lipids and blood pressure, is advocated by many, no published studies have yet demonstrated a clear reduction in risk of coronary events with this approach. Elucidation of risk factors and preventive strategies for accelerated atherosclerosis in SLE is the subject of ongoing research.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Gladman DD, Urowitz MB: Morbidity in systemic lupus erythematosus. J Rheumatol Suppl 1987, 14(Suppl 13):223–226.PubMedGoogle Scholar
  2. 2.
    Rubin LA, Urowitz MB, Gladman DD: Mortality in systemic lupus erythematosus: the bimodal pattern revisited. Q J Med 1985, 55:87–98.PubMedGoogle Scholar
  3. 3.
    Urowitz MB, Bookman AA, Koehler BE, et al.: The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976, 60:221–225.PubMedCrossRefGoogle Scholar
  4. 4.
    Urowitz MB, Ibanez D, Gladman DD: Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. J Rheumatol 2007, 34:70–75.PubMedGoogle Scholar
  5. 5.
    Manzi S, Meilahn EN, Rairie JE, et al.: Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145:408–415.PubMedGoogle Scholar
  6. 6.
    Petri M, Perez-Gutthann S, Spence D, Hochberg MC: Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992, 93:513–519.PubMedCrossRefGoogle Scholar
  7. 7.
    Bruce IN, Gladman DD, Urowitz MB: Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000, 26:257–278.PubMedCrossRefGoogle Scholar
  8. 8.
    Adams RJ, Chimowitz MI, Alpert JS, et al.: Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Circulation 2003, 108:1278–1290.PubMedCrossRefGoogle Scholar
  9. 9.
    Manzi S, Selzer F, Sutton-Tyrrell K, et al.: Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42:51–60.PubMedCrossRefGoogle Scholar
  10. 10.
    Roman MJ, Shanker BA, Davis A, et al.: Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399–2406.PubMedCrossRefGoogle Scholar
  11. 11.
    Rahman P, Urowitz MB, Gladman DD, et al.: Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol 1999, 26:2363–2368.PubMedGoogle Scholar
  12. 12.
    Bruce IN, Urowitz MB, Gladman DD, et al.: Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003, 48:3159–3167.PubMedCrossRefGoogle Scholar
  13. 13.
    Esdaile JM, Abrahamowicz M, Grodzicky T, et al.: Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331–2337.PubMedCrossRefGoogle Scholar
  14. 14.
    Bruce IN, Urowitz MB, Gladman DD, Hallett DC: Natural history of hypercholesterolemia in systemic lupus erythematosus. J Rheumatol 1999, 26:2137–2143.PubMedGoogle Scholar
  15. 15.
    Rahman P, Aguero S, Gladman DD, et al.: Vascular events in hypertensive patients with systemic lupus erythematosus. Lupus 2000, 9:672–675.PubMedCrossRefGoogle Scholar
  16. 16.
    Asia Pacific Cohort Studies Collaboration: Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. Circulation 2005, 112:3384–3390.CrossRefGoogle Scholar
  17. 17.
    Bostom AG, Rosenberg IH, Silbershatz H, et al.: Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med 1999, 131:352–355.PubMedGoogle Scholar
  18. 18.
    Stampfer MJ, Malinow MR, Willett WC, et al.: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268:877–881.PubMedCrossRefGoogle Scholar
  19. 19.
    Petri M, Roubenoff R, Dallal GE, et al.: Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996, 348:1120–1124.PubMedCrossRefGoogle Scholar
  20. 20.
    Roman MJ, Crow MK, Lockshin MD, et al.: Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007, 56:3412–3419.PubMedCrossRefGoogle Scholar
  21. 21.
    Ross R: Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.PubMedCrossRefGoogle Scholar
  22. 22.
    Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003, 107:363–369.PubMedCrossRefGoogle Scholar
  23. 23.
    Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499–511.PubMedCrossRefGoogle Scholar
  24. 24.
    Lee SS, Singh S, Link K, Petri M: High-sensitivity C-reactive protein as an associate of clinical subsets and organ damage in systemic lupus erythematosus. Semin Arthritis Rheum 2008, 38:41–54.PubMedCrossRefGoogle Scholar
  25. 25.
    Kiani AN, Magder L, Petri M: Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol 2008, 35:1300–1306.PubMedGoogle Scholar
  26. 26.
    Selzer F, Sutton-Tyrrell K, Fitzgerald S, et al.: Vascular stiffness in women with systemic lupus erythematosus. Hypertension 2001, 37:1075–1082.PubMedGoogle Scholar
  27. 27.
    Doria A, Shoenfeld Y, Wu R, et al.: Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003, 62:1071–1077.PubMedCrossRefGoogle Scholar
  28. 28.
    Toloza SM, Uribe AG, McGwin G Jr, et al.: Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004, 50:3947–3957.PubMedCrossRefGoogle Scholar
  29. 29.
    Ibanez D, Gladman DD, Urowitz MB: Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol 2005, 32:824–827.PubMedGoogle Scholar
  30. 30.
    Karp I, Abrahamowicz M, Fortin PR, et al.: Recent corticosteroid use and recent disease activity: independent determinants of coronary heart disease risk factors in systemic lupus erythematosus? Arthritis Rheum 2008, 59:169–175.PubMedCrossRefGoogle Scholar
  31. 31.
    Petri M, Lakatta C, Magder L, Goldman D: Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994, 96:254–259.PubMedCrossRefGoogle Scholar
  32. 32.
    Sachet JC, Borba EF, Bonfa E, et al.: Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 2007, 16:273–278.PubMedCrossRefGoogle Scholar
  33. 33.
    Wallace DJ, Metzger AL, Stecher VJ, et al.: Cholesterollowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. Am J Med 1990, 89:322–326.PubMedCrossRefGoogle Scholar
  34. 34.
    Rahman P, Gladman DD, Urowitz MB, et al.: The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs. J Rheumatol 1999, 26:325–330.PubMedGoogle Scholar
  35. 35.
    Johansson E, Forsberg K, Johnsson H: Clinical and experimental evaluation of the thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis 1981, 10:89–96.PubMedGoogle Scholar
  36. 36.
    Petri M, Yoo S-S: Predictors of glucose intolerance in systemic lupus erythematosus. Arthritis Rheum 1994, 37:S323.Google Scholar
  37. 37.
    Sherer Y, Shoenfeld Y: Antiphospholipid antibodies: are they pro-atherogenic or an epiphenomenon of atherosclerosis? Immunobiology 2003, 207:13–16.PubMedCrossRefGoogle Scholar
  38. 38.
    Ahmad Y, Shelmerdine J, Bodill H, et al.: Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 2007, 46:983–988.CrossRefGoogle Scholar
  39. 39.
    Nikpour M, Urowitz MB, Gladman DD: Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2005, 31:329–354, vii–viii.PubMedCrossRefGoogle Scholar
  40. 40.
    O’Leary DH, Polak JF, Kronmal RA, et al.: Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999, 340:14–22.PubMedCrossRefGoogle Scholar
  41. 41.
    van der Meer IM, Bots ML, Hofman A, et al.: Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation 2004, 109:1089–1094.PubMedCrossRefGoogle Scholar
  42. 42.
    Nallamothu BK, Saint S, Bielak LF, et al.: Electron-beam computed tomography in the diagnosis of coronary artery disease: a meta-analysis. Arch Intern Med 2001, 161:833–838.PubMedCrossRefGoogle Scholar
  43. 43.
    Asanuma Y, Oeser A, Shintani AK, et al.: Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2407–2415.PubMedCrossRefGoogle Scholar
  44. 44.
    Hosenpud JD, Montanaro A, Hart MV, et al.: Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 1984, 77:286–292.PubMedCrossRefGoogle Scholar
  45. 45.
    Nikpour M, Gladman DD, Ibanez D, et al.: Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. J Rheumatol 2009, 36:288–294.PubMedCrossRefGoogle Scholar
  46. 46.
    Bruce IN: ’Not only…but also’: factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44:1492–1502.CrossRefGoogle Scholar
  47. 47.
    Wajed J, Ahmad Y, Durrington PN, Bruce IN: Prevention of cardiovascular disease in systemic lupus erythematosus—proposed guidelines for risk factor management. Rheumatology (Oxford) 2004, 43:7–12.CrossRefGoogle Scholar
  48. 48.
    Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560–2572.PubMedCrossRefGoogle Scholar
  49. 49.
    Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227–239.PubMedCrossRefGoogle Scholar
  50. 50.
    Ridker PM, Danielson E, Fonseca FA, et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359:2195–2207.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  • Mandana Nikpour
  • Murray B. Urowitz
    • 1
  • Dafna D. Gladman
  1. 1.Toronto Western HospitalUniversity of Toronto Lupus Clinic and the Centre for Prognosis Studies in the Rheumatic DiseasesTorontoCanada

Personalised recommendations